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Summary
The wide availability of fibrinogen estimations based on the 
prothrombin time (PT-Fg) has caused concern about the variability and
clinical utility of fibrinogen assays. In a multi-centre study, we investi-
gated fibrinogen assays using various reagents and analysers. Clauss
assays generally gave good agreement, although one reagent gave 
15-30% higher values in DIC and thrombolysis. Two commercial 
reference preparations had much lower potencies than the manufactu-
rers declared, and plasma turbidity influenced parallelism in some
Clauss assays. PT-Fg assays gave higher values than Clauss and 
showed calibrant dependent effects, the degree of disparity correlating
with calibrant and test sample turbidity. Analyser and thromboplastin
dependent differences were noted. The relationship between Clauss and
PT-Fg assays was sigmoid, and the plateau of maximal PT-Fg differed
by about 2 g/l between reagents. ELISA and immunonephelometric 
assays correlated well, but with a high degree of scatter. Antigen levels
were higher than Clauss, but slightly lower than PT-Fg assays, which
appeared to be influenced by degraded fibrinogen. Clauss assays 
are generally reproducible between centres, analysers and reagents, but
PT-Fg assays are not reliable in clinical settings.
Introduction
Fibrinogen assays are performed in the investigation of haemor-
rhage, monitoring of thrombolytic therapy and in risk factor screening
for arterial disease. The Clauss fibrinogen assay (1), based on the
thrombin clotting time, is the most frequently used technique, but varies
greatly in the source and composition of reagents, as well as assay 
protocol. In developed countries, automated methods, based on photo-
optical principles, are most frequently used. Most assays are designed
for measuring low fibrinogen levels and may have different sensitivity
or accuracy for elevated fibrinogen. 
The choice of commercial calibrant plasma is clearly important and
it has been recommended that manufacturers calibrate against the Inter-
national Standard (IS) preparation (2). The 1st IS for plasma fibrinogen
has been available for many years (3), but some manufacturers of 
fibrinogen ‘standards’ have been slow to utilise it, and apparently 
calibrate against “in house” plasma pools or the College of American
Pathologists standard. The 1st IS was calibrated primarily by clottable
protein assays rather than by the Clauss technique (since any primary
standard must be calibrated by a direct or absolute measure), and 
a change to the IS could cause a significant shift in calibration values,
requiring new reference ranges.
The numerous types of coagulation analysers introduce further 
variables; many offer a fibrinogen estimation based on the change in
light scattering or optical density during the prothrombin time (the PT-
derived fibrinogen, PT-Fg). This method rapidly provides a fibrinogen
value and is used in approximately 50% of UK Haematology laborato-
ries (4). However, some PT-Fg methods give higher fibrinogen values
than the Clauss technique (2, 5-8), although the discrepancy is not 
consistent over a range of fibrinogen levels, and may depend on the 
clinical defect as well as the thromboplastin reagent used (7, 8). The PT-
Fg method gives apparently normal fibrinogen levels in certain clinical
states, where Clauss levels are reduced, e.g. dysfibrinogenaemia and
thrombolytic therapy. Despite these observations, some groups demon-
strated good comparability between Clauss and particular PT-Fg assays
(9-10), although the latter stated that precision was inadequate in PT-Fg
assays where the PT was prolonged (e.g. due to anticoagulants) and if
the fibrinogen level was high.
The purpose of this study was therefore to evaluate the most 
frequently used fibrinogen reference plasmas and reagents, in the two
most popular types of fibrinogen assay: the Clauss and PT-Fg methods,
using mechanical and photo-optical coagulometers. The evaluation was
performed on behalf of the Medical Devices Agency (MDA), the 
Department of Health, UK, and the British Committee on Standards in
Haematology. Detailed results are available in two MDA reports 
(11, 12).
Materials and Methods
Reference preparations, assay reagents and coagulometers were selected
from those most frequently used in the UK (as judged by UK NEQAS for Blood
Coagulation returns). Five centres took part, all experienced in performing 
coagulation tests. 
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Blood Samples
Blood samples were collected from: healthy normal subjects (n = 10); 
patients with: DIC [n = 7, defined by published criteria (13)], liver disease 
(n = 17), congenital hypofibrinogenaemia (n = 4), acute phase reaction (APR, 
4 with sepsis, 3 severe infection, 1 MI, 1 severe trauma, 1 chronic jaundice); 
or patients receiving unfractionated heparin therapy (n = 11), thrombolytic
therapy (n = 10), or oral anticoagulants (OAC, INR >2.5, n = 10). All blood
samples were collected with minimal venous stasis into 0.106 M trisodium
citrate. Plasma was prepared by double centrifugation at room temperature, 
at 2000  g for 15 min, to ensure platelet depletion, and stored in aliquots in 
polypropylene tubes at –70° C. 
Standards and Reference Plasmas
The potency of five commercial reference preparations was determined 
relative to a local working standard (WS), which had been calibrated against
the 1st IS for fibrinogen (89/644) (3). WS was prepared by pooling six fresh
plasma samples (selected for good optical clarity) from fasting, healthy, normal
subjects, and aliquots were rapidly frozen at –70° C. The potency of WS was
established in three laboratories by Clauss assay, using two commercial
reagents (Rg1 and Rg2, see below). These were used on each of two mechani-
cal (Amelung KC4A and KC10, Sigma-Aldrich Diagnostics, Poole, UK) and
two photo-optical coagulometers (CA-1000 and CA-6000, Sysmex UK Ltd,
Milton Keynes, UK). Two vials each of IS and WS were tested by each method
on each of two separate days, with a replicate series of single clotting times 
for each estimation, obtained in a balanced order. The relative potencies were
calculated using parallel line bioassay principles with statistical validation (see
below). 
The following commercial reference preparations (Rp1-Rp5) were evalua-
ted: Immuno Reference Plasma 100% (Technoclone Ltd, Dorking, UK), Dade
Behring Fibrinogen Standard (Dade Behring, Marburg, Germany), Verify®
Reference Plasma (Organon Teknika, Cambridge, UK), Diagen Fibrinogen
Standard Plasma (Diagnostic Reagents Ltd, Thame, UK), IL Test™ Calibra-
tion Plasma (Instrumentation Laboratory UK Ltd, Warrington, UK). 
Four additional plasmas were used for reference and quality control purpo-
ses: a lyophilised high fibrinogen preparation (designated HF, batch 970521),
(normal plasma was spiked with 95% clottable, purified fibrinogen); and three
plasmas from non-anticoagulated patients with normal coagulation, having a
range of fibrinogen levels: 1-1.5 g/l (QC1), 2-3 g/l (QC2), and 4-5 g/l (QC3).
Within run variability was assessed in each method by performing 12 replicate
assays (with duplicate clotting times) of the three different QC plasmas. 
Between run variability was assessed in each method by assaying QC1 with
each batch of patient samples.
Assays
The sensitivity and linearity of the calibration curves obtained for each 
commercial reference preparation in the modified Clauss assay (14), were 
assessed over a wide series of dilutions. The potency of each commercial 
reference preparation was determined in relation to WS using replicate assays
tested in a 6  6 Latin square design, using two Clauss reagents (Rg1 and Rg2,
see below). These were used on photo-optical (1 CA-1000 and 2 CA-6000)
and mechanical (1 KC4A and 2 KC10) coagulometers amongst 3 partici-
pating sites, so that 72 potency estimates of each preparation were obtained.
Reference preparations were tested at four dilutions in duplicate (assays accep-
ted with minimum of three dilutions giving valid results).
The performance of four commercial Clauss reagents (Rg1-Rg4): Immuno
AG Fibrinogen Reagent (Technoclone), Fibrinogen Determination Reagent
(Dade Behring), Fibriquick thrombin reagent (Organon Teknika), and IL
Test™ Fibrinogen-C kit (Instrumentation Laboratory), was assessed using 
clinical samples. Nine instruments, comprising mechanical (1 KC4A, 
2 KC10) and photo-optical coagulometers [1 CA-1000, 2 CA-6000, 
1 ACL-300R and 2 ACL-3000 (Sysmex and Instrumentation Laboratory)]
were used amongst four different laboratories. The Fibrinogen-C kit was only
used on ACL coagulometers, for which it was specifically designed. A single
calibration curve, constructed by taking the mean of ten curves, was used
throughout the study for each reagent/instrument combination. Clinical 
samples were assayed once by each centre, in batches of ten, with duplicate
clotting times at a dilution of 1/10. For low fibrinogen levels (<1.0 g/l), a 1/5 
dilution was used; for high fibrinogen levels (>4.0 g/l), a 1/20 dilution was
used. The CA-analysers were set for re-dilution: <1.0 g/l and >4.0 g/l.
The commercial reference preparations were assessed by the PT-Fg method,
using three ACL and three CA coagulometers (ACL-300/ACL-3000 and 
CA-1000/CA-6000). An optically clear recombinant thromboplastin, Innovin
(Dade Behring) and a relatively turbid rabbit brain thromboplastin, PT Fib 
HS Plus (PT-FibHS+, Instrumentation Laboratory) were selected for study. The
instruments were separately calibrated with each thromboplastin, and each of
the following plasmas: WS, HF, Rp1-Rp5. Plasma samples with high, normal,
or low fibrinogen levels (QC1, QC2, QC3) were assayed in duplicate in a 
balanced order, against each of these calibrations. An acid wash was performed
between each calibration, to prevent any possible carry-over of reagent. The
performance of the PT-Fg methods was also studied, by assaying the 79 
clinical samples against WS. These assays were performed in two separate 
series, where the QC plasmas were tested at the beginning and end of the run to
check both for within run precision and temporal drift. 
Several other fibrinogen assays were performed for reference purposes.
Clottable protein assays (3) were performed by a modified clot extraction 
method (15). An immuno-nephelometric assay for fibrinogen antigen (Fg:Ag)
on the BN-100 analyser, using a commercial latex reagent (Dade Behring), 
and an ELISA method using polyclonal antisera (Dako Ltd, Ely, UK) were 
performed, all standardised using WS. D-dimer (Agen Dimertest Gold kit, 
Quadratech, Surrey, UK) and fibrinogen specific degradation products
(FgDP, Organon Teknika) were assayed in the clinical samples by ELISA. The
opacity of each reference preparation, QC plasma, and clinical sample was
assessed spectrophotometrically using doubling dilutions, at 405, 540, and
650 nm.
Potency Estimation and Statistical Analysis
The dose-response curve of each fibrinogen reference preparation was
checked for linearity and parallelism to the calibrator (i.e. 1st IS or WS). These
data were analysed by parallel-line bioassay (16) relating log-transformed 
dose, as this gave the best linear dose-response curves with homogeneity of 
variance across the response groups. An analysis of variance provided an 
assessment of linearity and parallelism and estimates of relative potency were
produced from the fitted lines together with 95% confidence limits. Deviations
from linearity and parallelism were considered significant at p <0.05.
For imprecision studies and clinical assays, potency values were obtained
from the coagulometer software, or in the case of the semi-automated mechani-
cal end-point systems, by computer software using linear regression analysis.
Unless otherwise stated, the arithmetic mean is shown. The distribution of data
was examined by measuring skewness and kurtosis, plotting histograms, and
where necessary, assessing normality using the Kolmogorov-Smirnov test. 
Paired t-tests or non-parametric tests (Wilcoxon rank sum paired test) were
used as appropriate to the distribution. In regression analysis, outliers were 
rejected where they were outside the 95% confidence interval, or where
they were clearly separated from the main data cluster (by subjective assess-
ment).
Results
Calibration curves were generally linear between 1/5 and 1/30 
dilutions with IS on the KC-analysers. With WS and the commercial
standards (Rp1-5), linearity was usually only obtained on CA-ana-
lysers, when the 1/5 dilution was omitted (regardless of the analyser),
resulting in calibration curves from 3/20 to 1/30 dilutions. A total of 16
potential calibration values were generated for WS, but very poor 
parallelism between IS and WS was obtained, with Rg2 in three 
estimates on the CA-analysers, even when the extreme dilutions were
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omitted (non-parallel results excluded from analysis). The geometric
mean potency of WS was 2.33 g/l (95% confidence limits 2.28-2.38 g/l).
An acceptable degree of imprecision was obtained for the three QC
plasmas in Clauss assays [intra-assay coefficient of variation (cv) 5.9%,
inter-assay cv 8.5%]. Greatest variability was observed using the 
KC-coagulometers (cv 9.9%). Similar imprecision was obtained 
for each reagent; Rg4 gave cv’s between 3.29 and 4.07% on ACL 
analysers. The overall variability in PT-Fg assays, detected using the
QC plasmas, was similar to that for the Clauss assays (pooled intra-
assay cv 5.7%). The imprecision tended to be smaller (cv 3-6%) with
the ACL- than with the CA-analysers (cv 8-15%). This difference was
mainly due to high variability with PT-FibHS+ reagent on the CA-
analysers, and this reagent also showed higher overall variability than
Innovin (cv 6-13% vs. 6-8%).
Clauss Fibrinogen Assay
The geometric mean potency estimate of each commercial reference
preparation was calculated from a maximum of 72 assays against WS
(Table 1). Non-parallel dose/response lines occurred more often with
Rp2, but were independent of the reagent used. Potency estimates were
therefore not available for this preparation in two assay sets (using Rg1
and Rg2), both on CA-analysers. These non-parallel responses were
excluded, and potency estimates were analysed from 60 of the 72
assays.
There was generally close agreement between centres and analysers
for each reference preparation, with only a small spread of values 
(Table 1). Overall, there were no significant differences between the
values generated in each centre, for any of the commercial reference
preparations. There was also no significant difference in mean values
between Rg1 and Rg2 Clauss reagents (2.55 and 2.61 g/l respectively).
However, when data for individual standards were analysed, the CA-
analysers consistently gave slightly higher values than KC-analysers
(overall mean ± SD 2.66 ± 0.27 and 2.51 ± 0.27 g/l, respectively). 
The estimated potency of two of the commercial reference prepara-
tions (Rp1 and Rp2) was in good agreement with the potency declared by
the manufacturer (Table 1). Rp4 had a lower Clauss value than the ma-
nufacturer’s declared potency of 2.50 g/l, although the latter potency
was within the observed range of results and 95% confidence intervals.
Two further commercial preparations (Rp3 and Rp5) showed 11-17% 
lower potency values than declared by the manufacturers. The declared
potencies of Rp3 and Rp5 did not fall within the range of observed
Clauss values. There was closer agreement between clottable protein
and Clauss assay results than with the manufacturers’ declared
potencies. WS contained 2.29 g/l fibrinogen by clottable protein
assay,  compared with the value of 2.33 g/l obtained in the Clauss
assays.
The mean variability in the results using the 79 clinical samples was
generally higher than with the quality control plasmas, particularly in
the thrombolytic therapy group, although this was not caused by any
particular reagent or instrument. There were no significant differences
in mean fibrinogen between the four Clauss reagents (range 2.65 to
2.71 g/l). However, when the results were divided into different clinical
groups (data not shown), the results obtained with Rg1, Rg2, and Rg3
were generally about 15% lower than the results with Rg4 in DIC, and
up to 20% lower in thrombolytic therapy. There were no overall 
statistically significant differences between centres and no clinically
significant differences between analysers (mean ± SD, CA-analysers
2.63 ± 1.84, KC-analysers 2.84 ± 1.86 g/l, p <0.0001). When the results
for each Clauss reagent were compared with the mean of the values for
the other three reagents, good agreement was obtained over the normal
range (maximum mean difference 0.04 g/l). However, the relationship
between the results obtained with Rg4 and other reagents appeared to
change with increasing magnitude of fibrinogen concentration. The two
samples with the highest fibrinogen concentration gave the greatest
scatter in results.
PT-derived Fibrinogen
It was not possible to calibrate the ACL analysers for PT-Fg assay,
using PT-FibHS+ reagent, when reference preparation HF (declared
potency 4.65 g/l) was used. The instrument would not accept a calibrant
value of >4.5 g/l, but attempts to calibrate by entering a nominal value
of 4.5 g/l were also unsuccessful. This may have been due to short 
clotting times, or the degree of light scatter being outside set limits.
ACL analysers were successfully calibrated with HF using Innovin
reagent, when a nominal value of 4.5 g/L was entered. CA-analysers
could be calibrated with HF provided that higher dilutions were used, to
obtain a linear dose response curve. Some calibration failures occurred
with Rp2 plasma as calibrant on the ACL, with Innovin reagent. 
The software failed to report results for QC3 plasma, as the values 
were outside the set limits for the assay.
The PT-Fg values for the three QC plasmas were invariably higher
(regardless of the commercial reference plasma used) than those from
Clauss or clottable protein methods. The QC plasma results provided
evidence that the choice of calibrator affected the PT-Fg potency 
estimate (Table 2). Results with WS as calibrant were closest to those
from Clauss and clottable protein assays. These were followed by the
estimates obtained using Rp1 and HF as calibrants. The most discrepant
values were obtained when Rp2 was calibrant. Correction of the results
according to the calibrant potency as measured in Clauss assays, failed
to remove the discrepancies. The difference in potency assignment was
most marked with the high fibrinogen QC sample (QC3), with values
varying by more than 2 g/l.
PT-Fg variability between reagents/analysers was greater in clinical
than QC samples, particularly in thrombolytic therapy. Assays using
Innovin consistently showed higher values (mean ± SD 3.56 ± 2.38, 
range 0.52-10.48 g/l) than those using PT-FibHS+ (3.24 ± 1.98, 
0.59-7.71 g/L, p <0.0001), although there was good correlation 
(r = 0.97). Data analysis by clinical subgroup showed no significant 
differences in mean values for each reagent in: normal subjects, liver
disease, or heparin therapy. However, Innovin gave significantly higher
PT-Fg values in DIC (mean ± SD: 1.58 ± 0.59 vs. 1.31 ± 0.52 g/l, 
p <0.02), oral anticoagulation (4.56 ± 1.42 vs. 3.81 ± 1.11 g/l, p = 0.005),
thrombolytic therapy (2.51 ± 0.73 vs. 2.09 ± 0.68 g/l, p <0.01), and in 
Table 1 Declared and estimated potencies of reference preparations. The
declared potency provided by the manufacturer, mean Clauss fibrinogen potency
(n = 60, range in parenthesis), and clottable protein levels are shown 
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the “high fibrinogen” group (7.27 ± 1.06 vs. 6.16 ± 0.92 g/l, p <0.01). 
Hypofibrinogenaemia samples gave values of: 1.40, 0.52, 1.27, and
1.09 g/l for Innovin and 1.19, 1.28, 1.06, and 1.79 g/l for PT-FibHS+,
although there was great variability in the results. Clear discrepancies
in the results with these two reagents were also observed in other 
samples; differences of 0.5-1.0 g/l were seen in samples with
low or normal fibrinogen levels, and 2.0-3.0 g/l in high fibrinogen
samples.
Significantly higher PT-Fg levels were measured on ACL-analysers
compared to CA-analysers (Table 3). There were no significant 
differences between different ACL analyser models, but the CA-6000
gave higher values (similar to the ACL analysers) than the CA-1000.
Higher levels were obtained with ACL analysers for thrombolytic
therapy (mean ± SD 2.40 ± 0.74 vs. 2.07 ± 0.64 g/l, p <0.001), oral 
anticoagulant (4.29 ± 1.12 vs. 3.88 ± 1.18 g/l, p = 0.023), and “high 
fibrinogen” groups (7.38 ± 1.19 vs. 6.26 ± 1.04 g/l, p <0.001). Hypo-
fibrinogenaemia patients gave higher values by the CA-analysers 
(1.24 ± 0.12 vs. 1.01 ± 0.24 g/l, p = 0.028). 
Comparison of Clauss and PT-derived Fibrinogen
PT-Fg was higher than Clauss fibrinogen (n = 79, mean ± SD: 3.39
± 2.16 and 2.68 ± 1.82 g/l, p<0.0001, respectively) in all clinical
groups, except for the four hypofibrinogenaemia patients (1.21 ± 0.22
and 1.20 ± 0.16) and the normal subjects (2.16 ± 0.54 and 2.10 ± 0.41).
There was an apparent correlation (r = 0.95) between the two types of
assay, but the best fit line was sigmoid (Fig. 1a). The thrombolytic
therapy samples clearly distorted this relationship, but a sigmoid curve
fit was still obtained after their exclusion. A similar type of curve fit 
applied to both thromboplastins (Fig. 1b), although there was less 
scatter with PT-FibHS+ than Innovin. The curve reached a plateau 
earlier with PT-FibHS+, giving a lower upper limit of measurement 
for PT-Fg (approximately 7 g/l, compared to 9 g/l with Innovin and
equivalent to 5.0-6.0 g/l by Clauss assay).
Plasma Opacity Analysis
The absorbance of doubling dilutions of each reference preparation
was measured in a spectrophotometer at three wavelengths (405, 540,
650 nm), selected to cover different regions of the visible spectrum.
One of these wavelengths was similar to that used by the photo-optical
coagulometers when coagulation tests are performed (660 nm). The 
reference preparations showed a wide range of absorbance values 
(Table 4). Rp2 gave the highest absorbance at each wavelength, even
after 1/8 dilution, while WS had relatively low absorbance, in keeping
with its apparent optical clarity. The degree of discrepancy between
Clauss and PT-Fg values appeared to correlate (Fig. 2) with the absor-
bance of the PT-Fg calibration plasma (r = 0.83, p = 0.02 and r = 0.76,
p <0.05, for QC1 and QC3 at 650 nm). Similar results were obtained at
405 and 540 nm. The most turbid reference plasma (Rp2) gave the 
greatest difference between assays, whereas the least turbid (WS) gave
the lowest discrepancy. A wide range of plasma opacities existed in the
clinical samples (e.g. range of absorbance values obtained for 1/5 
diluted samples at 405 nm: 0.137-2.680; 540 nm: 0.040-1.917, 650 nm:
0.022-1.410). In some samples, a considerable portion of this was 
related to icterus and/or lipaemia. When all of these samples were 
analysed as a group, there was no obvious relationship between plasma
opacity and the discrepancy between Clauss and PT-Fg assays. How-
ever, analysis of the normal control and oral anticoagulant samples 
(to remove the effects of abnormal fibrinogen molecules and liver 
dysfunction) showed a significant correlation between absorbance and
the discrepancy between PT-Fg and Clauss assays (405 nm: r = 0.50, 
Table 2 PT-Fg assays (combined results from all
laboratories, reagents and analysers) of three quality
control plasmas using different reference plasmas as
calibrants. Mean potencies are shown, with the SD in
parenthesis (n = 12). The Declared Calibrant Potency is
that declared by the manufacturer, or in the case of WS,
the value obtained by Clauss assay. * Values exclude
data from ACL-analysers with IL PT-FibHS+,
where calibration failed; **n = 9 (calibration failed with
Rp2 and Innovin on the ACL) 
Table 3 Effect of coagulation analyser on PT-Fg
assays (g/l) in clinical samples 
Table 4 Absorption values of 1/8 diluted reference plasmas at three wave-
lengths nb. All preparations had been lyophilised with the exception of WS
1001
Mackie et al.: Performance Evaluation of Fibrinogen Assays
p = 0.025; 540 nm: r = 0.55, p = 0.013; 650 nm: r = 0.56, p = 0.01). A
similar correlation was obtained with PT-Fg, but not with Clauss or
Fg:Ag assays (data not shown).
Fibrinogen Antigen Assays
Fg:Ag was measured by ELISA in 79 samples (mean ± SD: 3.19 ±
2.08 g/l). There was sufficient plasma in 68 samples, to compare both
Fg:Ag assays. These showed no significant difference, although there
was a trend towards lower levels by the immuno-nephelometric method
than ELISA (mean ± SD: 3.02 ± 1.63 and 3.25 ± 2.10 g/l, respectively).
A good correlation (r = 0.92, p <0.0001, y = 0.71 + 0.71) was 
obtained, although there was a high degree of scatter. Fg:Ag assays 
gave significantly higher values than Clauss assays (mean ± SD: 2.92 ±
1.86 g/l, p <0.0001 and p <0.003), but slightly lower values than PT-Fg
assays (3.72 ± 2.16 g/l, p <0.001 and p = 0.026). A good correlation
was obtained between Fg:Ag, and either Clauss (r = 0.86, p <0.0001) or
PT-Fg assays (r = 0.88, p <0.0001) although there was a high degree of
scatter (data not shown). Closer agreement was obtained between
Fg:Ag and PT-Fg than Clauss fibrinogen. In patients with elevated 
fibrinogen levels (>4.5 g/l), there were large discrepancies between
Fig. 1a Influence of clinical group on the relationship
between PT-Fg and Clauss fibrinogen assays. Results
are shown for disseminated intravascular coagulation
(), liver disease (), congenital hypofibrinogenaemia
(), heparin therapy (✚), thrombolytic therapy (),
oral anticoagulants (), acute phase reaction (),
normal controls () and quality control samples ().
The line of best fit is shown for all data (solid line)
and after excluding the thrombolytic therapy samples
(broken line). 
Fig. 1b Comparison of PT-Fg values obtained with
Innovin () or PT-FibHS+ () and mean Clauss
fibrinogen
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either Clauss or PT-Fg assays and Fg:Ag, and there was some variation
depending on the type of clinical problem.
Influence of Fibrin Degradation on Fibrinogen Assay
The levels of D-dimer and FgDp (range 15-6439 ng/ml and 
220-18,000 ng FEU/ml, respectively, excluding the thrombolytic 
therapy samples), showed no correlation with the fibrinogen levels in
each assay type, or with the discrepancy between Clauss and PT-Fg 
results. D-dimer levels were not raised in the majority of thrombolytic
therapy samples (median 131, range 32-1751 ng/ml), but FgDP levels
were abnormally high in all except one (median 18,000, range 
220-21,380 ng FEU/ml), and were associated with a large discrepancy
between the Clauss and PT-Fg assays. When this inter-assay discre-
Fig. 3 The influence of degraded fibrinogen on PT-Fg
and Clauss assays. The difference between PT-Fg and
Clauss assays, as a function of Clauss fibrinogen con-
centration, was plotted against the ratio of fibrinogen
degradation products (FDP) to crosslinked fibrin degra-
dation products. For key, see Fig. 1a
Fig. 2 The relationship between calibrant plasma ab-
sorbance and discrepancy between PT-Fg and Clauss
assays. The difference between PT-Fg and Clauss assay
values obtained for QC1 plasma, when assayed against
each calibrant, was plotted against the absorbance
(at 405 and 650 nm) of a 1/8 dilution of each calibrant
plasma
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pancy was weighted according to the Clauss value, and plotted against
the ratio of FgDP/D-dimer, the thrombolytic therapy group were 
clearly separated from other groups, having a high difference per gram
of Clauss fibrinogen (Fig. 3). 
Discussion
The use of fibrinogen assays in the investigation of haemorrhage is
well established. Prospective studies indicate that fibrinogen is a 
predictor of cardiovascular events in arterial disease (27); this statistical
association remains, regardless of the fibrinogen assay type, although
immunoassays could give better prediction than Clauss assays (28, 29).
Fibrinogen levels may also be increased due to physiological changes,
oral contraceptives, and acute phase reaction (30-33), and the contri-
bution to thromboembolism in these situations remains unclear. The
measurement of fibrinogen in risk factor screening requires standar-
dised and reproducible assays, which can be universally interpreted. A
great variety of methods, reagents and analysers are used for fibrinogen
assay (17, 18), and laboratories focus on ease of use, throughput and
cost. The widespread availability of the PT-Fg (9, 19-25) has raised 
issues about the variability and clinical utility of different fibrinogen 
assays (2, 5-8, 26). Most studies suggest disparity between PT-Fg and
Clauss assays, but have been limited to particular reagent/analyser
combinations; there is little information concerning reagent, analyser
and calibrant related discrepancies within each method. We investiga-
ted these variables in a multi-centre study. For logistical reasons and to
overcome turbidity problems associated with the 1st IS, an optically
clear working standard (WS) was prepared. This was used as the main
reference preparation in subsequent studies. 
The dilution range yielding linear calibration curves for normal 
plasma by Clauss assay varied depending on the analyser, due to 
sensitivity differences and accuracy of clot detection. There was an 
acceptable degree of imprecision and agreement for all Clauss assays
with no significant differences between centres or analysers. The only
Clauss reagent related discrepancies were seen with Rg4 (only used on
ACL analysers, for which it was optimised), which gave higher values
in DIC and thrombolytic therapy. This reagent had a relatively low
thrombin concentration (35 u/ml), and contained calcium ions, which
may have improved clot detection with abnormal fibrinogen molecules.
These differences would not cause clinically significant problems in
routine practice, provided that only a single Clauss fibrinogen method
was in use. Reference plasma Rp2 exhibited a number of non-parallel
dose response curves, which may have been related to its increased 
turbidity, since plasmas with low turbidity as judged by photometry
gave no calibration problems. 
Two reference plasmas (Rp3 and Rp5) had mean Clauss values 
lower than the declared potency, and this was of clinical significance.
The Clauss assays generally showed good agreement with clottable
protein assays. However, this type of problem (34) has improved, since
a previous report (35) suggested that commercial standards deviated
from their declared value by as much as 80%, using clottable protein 
assays. 
It was not possible to calibrate the ACL-analysers for PT-Fg when
the high fibrinogen plasma and rabbit brain thromboplastin were used,
even when nominal, low fibrinogen values were entered. This problem
appeared to involve both reagent turbidity (7) as well as programming
limitations of the analysers. A similar problem did not occur on the 
CA-analysers, although the manufacturers do advise calibration with
fresh, optically clear plasma. PT-Fg values were invariably higher than
those obtained by Clauss or clottable protein methods, regardless of the
commercial reference plasma used, but the PT-Fg potency estimates
were closest to the Clauss values when WS was used as calibrant. The
largest PT-Fg estimates were obtained using the plasma with the 
highest relative turbidity. Since both types of analyser utilise a light
scattering principle for clot detection, with a wavelength of approxima-
tely 660 nm, it is not surprising that turbid plasmas influence their 
performance, particularly when they have high absorbance in that 
spectral region. Correction of the results to allow for the differences
between the manufacturer’s and the estimated potencies in Clauss 
assays, did not remove the discrepancies in PT-Fg potency. The discre-
pancy between calibrants was greatest when a high fibrinogen plasma
was studied, with values varying by more than 2 g/l. The differences in
potency estimates are likely to be due to the calibration procedures used
by the manufacturer. The use of the 2nd IS (98/612) for potency 
assignment may help to resolve the problem, since this standard has 
been prepared by detergent treatment of plasma, has high solubility 
and good optical clarity, which reduces any turbidity problems (36). In
normal and oral anticoagulant test samples, absorbance was correlated
with the degree of discrepancy in PT-Fg assays. This was not observed
when all clinical samples were studied, probably due to the effects 
of confounding variables such as: abnormal fibrinogen molecules, 
lipaemia and icterus.
Differences in PT-Fg values were observed between the CA-1000
and CA-6000, as well as between CA- and ACL-analysers. Contribu-
tory factors may be the use of different cuvette types and the calibra-
tion method for CA-analysers, based on a single measured point and 
a hypothetical zero, with the assumption that a linear relationship 
exists between concentration and light scatter. The PT-Fg assays were
influenced by the thromboplastin reagent, and the degree of difference
could have caused errors in the clinical management of patients with
decreased or low normal fibrinogen levels, while patients with in-
creased fibrinogen showed differences as high as 3 g/l. This may also
be related to the large turbidity differences between the thromboplastin
reagents (7), which will influence basal light scatter on the analysers. A
small change in light scatter with the optically clear Innovin would be
associated with a greater change in fibrinogen concentration than would
have occurred with the turbid PT-FibHS+. 
The great disparity between PT-Fg and Clauss assays in thrombo-
lytic therapy is well recognised (5, 9, 25), and suggests that the PT-Fg
assay is influenced by partially clottable fibrinogen. The discrepancy
between the two assays was associated with FgDP, but not D-dimer
concentration. Since FgDP retain at least one fibrinopeptide A domain
(37), they are capable of joining fibrin strands, but cause polymer 
termination. This may delay clot detection in the Clauss technique, 
although a large opacity change may still be achieved, giving a higher
PT-Fg level. Such an effect would become accentuated as the fibrino-
gen level fell, i.e. in the diluted plasma of a Clauss assay. This could
contribute to relatively low Clauss values and higher PT-Fg fibrinogen
values, whereas Fg:Ag levels may be unaffected. In fact, the addition of
early fibrinogen degradation products has been shown (38) to cause a
dose-dependent increase in Clauss and PT-Fg assays, whereas inter-
mediate and late products increase PT-Fg, but decrease Clauss results.
More turbid fibrin gels are formed at lower thrombin concentrations
(10). The thrombin concentration generated in the PT-Fg method 
is substantially lower (on a U/ml basis) than that used in the Clauss 
assay, while the fibrinogen concentration is 2.5- to 5-fold higher, and 
this may influence the results under conditions of abnormal fibrin 
polymerisation. 
Results from the Clauss and PT-Fg assays followed a sigmoid rela-
tionship. This may partly be explained by PT-Fg methods having upper
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cut-off limits, which vary depending on the analyser, while at lower 
fibrinogen levels there is a sensitivity problem, since the degree of
change in light scatter is small. This makes it difficult to apply data 
correction algorithms to make the assays equivalent, as some have 
suggested. The PT-Fg measuring range of the thromboplastin reagents
differed, due to variability in the fibrinogen level at which a plateau in
the sigmoid curve was reached. It remains to be established whether
this effect is constant for different batches of the same reagents, and is
a general phenomenon with all thromboplastins. 
No significant differences were observed between the two Fg:Ag 
assays, which showed a good correlation, despite a relatively high 
degree of scatter. The latter is likely to be due to differences in epitope
specificity of the antibodies (e.g. the polyclonal antibodies in the ELISA
assay cross-react with FDPs), and the binding affinities, resulting in 
differences in sensitivity and precision (39). Fg:Ag levels were 
generally higher than Clauss fibrinogen levels, but slightly lower than
the PT-Fg values. The discrepancy between Fg:Ag and Clauss values
was expected, since the former also measures non-functional and some
degraded forms of fibrinogen. 
The large number of assays and the limited volumes of clinical 
samples meant that only single batches of each reference plasma 
and reagent could be studied and it is possible that some of the discre-
pancies may be batch-dependent. We understand that Rp2 is no longer
commercially available, but the results have demonstrated that refe-
rence preparations with high turbidity may cause calibration problems
in both Clauss and PT-Fg assays. 
In conclusion, there were clinically significant discrepancies be-
tween observed and declared potencies for some commercial reference
plasmas, and these were amplified in PT-Fg assays. The optical clarity
of the calibrant plasma had a significant impact on Clauss and PT-Fg
assays. PT-Fg levels varied according to the thromboplastin reagent
and analyser used, and there was a sigmoid relationship with Clauss 
assays. The PT-Fg and Fg:Ag assays yielded similar values in many
samples, and PT-Fg assays were not sensitive to FgDP, and may not
therefore reflect the true clinical situation. Clinical laboratories should
be aware of these discrepancies when selecting fibrinogen assay 
methods for local use. Pt-Fg assays may be less reliable than Clauss in
the investigation of bleeding diathesis, and may be inaccurate in 
samples with high fibrinogen. It is essential that individual laboratories
and multi-centre studies standardise to a particular fibrinogen assay 
method. 
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